ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

XOMA XOMA Royalty Corporation

25.11
-0.15 (-0.59%)
20 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
XOMA Royalty Corporation NASDAQ:XOMA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.15 -0.59% 25.11 13.67 43.60 25.99 24.85 25.99 28,369 01:00:00

XOMA to Present at Upcoming Investor Conferences in March

28/02/2024 12:30pm

GlobeNewswire Inc.


XOMA Royalty (NASDAQ:XOMA)
Historical Stock Chart


From Dec 2023 to Dec 2024

Click Here for more XOMA Royalty Charts.

XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at the following March 2024 investor conferences:

  • The 44th Annual TD Cowen Health Care Conference taking place March 4-6, 2024, in Boston, MA.  Owen Hughes, Chief Executive Officer, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat on Wednesday, March 6, 2024, at 10:30 AM ET.  The presentation can be accessed at https://bit.ly/4939Ico.
  • The Leerink Partners 2024 Global Biopharma Conference, which is being held March 11-13, 2024, in Miami, FL.  Mr. Hughes will present the corporate overview on Monday, March 11, 2024, at 10:40 AM ET.  The presentation can be accessed at https://bit.ly/3SxDK0E.

XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event.

About XOMA CorporationXOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com.

  
XOMA Investor ContactXOMA Media Contact
Juliane SnowdenKathy Vincent
XOMA CorporationKV Consulting & Management
+1 646-438-9754+1 310-403-8951
juliane.snowden@xoma.comkathy@kathyvincent.com
  

1 Year XOMA Royalty Chart

1 Year XOMA Royalty Chart

1 Month XOMA Royalty Chart

1 Month XOMA Royalty Chart

Your Recent History

Delayed Upgrade Clock